This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
infection control | 572 |
optimal control | 452 |
health care | 426 |
control group | 425 |
mg kg | 418 |
intensive care | 357 |
public health | 335 |
pg ml | 276 |
ng ml | 275 |
gene expression | 271 |
cell lines | 237 |
septic shock | 237 |
care unit | 225 |
significantly higher | 224 |
united states | 212 |
present study | 209 |
blood flow | 202 |
cell line | 199 |
hand hygiene | 198 |
pregnant women | 191 |
clinical signs | 185 |
blood pressure | 183 |
oxidative stress | 182 |
infectious diseases | 179 |
statistically significant | 178 |
significant difference | 173 |
breast cancer | 170 |
two groups | 169 |
cancer cells | 165 |
disease control | 159 |
blood samples | 155 |
control measures | 154 |
results suggest | 151 |
significant differences | 151 |
nitric oxide | 146 |
risk factors | 145 |
organ failure | 143 |
significantly increased | 142 |
mean age | 140 |
cell proliferation | 139 |
important role | 138 |
mrna expression | 136 |
gestational age | 136 |
mechanical ventilation | 135 |
cell cycle | 134 |
vector control | 134 |
peripheral blood | 133 |
immune system | 128 |
western blot | 126 |
inflammatory response | 125 |
staphylococcus aureus | 123 |
immune response | 122 |
endothelial cells | 115 |
world health | 115 |
smooth muscle | 115 |
protein expression | 114 |
cardiac output | 114 |
statistical analysis | 114 |
nosocomial infection | 113 |
critically ill | 113 |
group i | 111 |
significant increase | 111 |
birth control | 110 |
significantly lower | 107 |
growth factor | 106 |
health organization | 106 |
acute respiratory | 105 |
amino acid | 103 |
body weight | 102 |
infectious agents | 101 |
data suggest | 101 |
birth weight | 97 |
time pcr | 97 |
respiratory tract | 96 |
septic patients | 96 |
multiple organ | 96 |
stem cells | 96 |
side effects | 95 |
plasma levels | 94 |
care settings | 93 |
mrna levels | 93 |
significantly reduced | 93 |
apache ii | 93 |
performed using | 92 |
cancer cell | 92 |
flow cytometry | 91 |
nosocomial infections | 90 |
cell death | 90 |
dependent manner | 89 |
bone marrow | 89 |
reproduction number | 88 |
ill patients | 88 |
results showed | 87 |
first trimester | 87 |
necrosis factor | 87 |
previous studies | 87 |
pulmonary artery | 85 |
infectious disease | 83 |
significantly different | 83 |
increased risk | 82 |
escherichia coli | 81 |
high levels | 81 |
ml min | 81 |
may contribute | 79 |
medical center | 79 |
laboratory animal | 78 |
arterial pressure | 78 |
heart rate | 78 |
tumor necrosis | 77 |
amino acids | 77 |
results indicate | 76 |
control strategies | 76 |
infected cases | 75 |
cell viability | 75 |
research complications | 75 |
fetal growth | 74 |
control problem | 74 |
basic reproduction | 74 |
immunodeficient mice | 73 |
resistant staphylococcus | 73 |
serum levels | 72 |
arterial blood | 72 |
may play | 72 |
mortality rate | 72 |
logistic regression | 72 |
severe acute | 72 |
three groups | 72 |
antimicrobial resistance | 71 |
care facilities | 71 |
new zealand | 71 |
significantly decreased | 71 |
first time | 70 |
lymph nodes | 70 |
high risk | 70 |
may lead | 69 |
adhesion molecules | 69 |
icu patients | 69 |
acute phase | 68 |
real time | 68 |
lg ml | 68 |
patients undergoing | 68 |
expression levels | 68 |
chain reaction | 67 |
group ii | 67 |
determine whether | 67 |
clinical trials | 67 |
neonatal intensive | 67 |
measured using | 66 |
polymerase chain | 66 |
social distancing | 66 |
animal medicine | 66 |
doc id | 65 |
cord uid | 65 |
vascular resistance | 65 |
ob gyn | 64 |
developing countries | 63 |
infected individuals | 63 |
biological control | 63 |
patient care | 63 |
protein levels | 63 |
control programs | 63 |
nervous system | 63 |
may also | 63 |
care units | 62 |
kg day | 62 |
standard precautions | 62 |
may occur | 62 |
western blotting | 62 |
laboratory mice | 62 |
myocardial infarction | 62 |
social control | 62 |
stem cell | 62 |
renal failure | 61 |
findings suggest | 60 |
reactive oxygen | 60 |
within hours | 60 |
conspiracy theories | 60 |
monoclonal antibodies | 60 |
type i | 60 |
control groups | 60 |
amniotic fluid | 60 |
insulin resistance | 60 |
trauma patients | 60 |
central venous | 60 |
ml kg | 59 |
extracellular matrix | 59 |
cell surface | 59 |
transcription factor | 59 |
long term | 59 |
mononuclear cells | 59 |
venous blood | 59 |
mg dl | 58 |
widely used | 58 |
results show | 58 |
epithelial cells | 58 |
united kingdom | 58 |
lung injury | 57 |
mean arterial | 57 |
significant reduction | 57 |
dna damage | 57 |
differential equations | 57 |
healthcare workers | 56 |
mg ml | 56 |
cardiac surgery | 56 |
prospective study | 56 |
higher levels | 56 |
may cause | 56 |
years old | 56 |
determined using | 56 |
blot analysis | 55 |
cell culture | 55 |
lipid peroxidation | 55 |
epidemic control | 55 |
clostridium difficile | 54 |
risk factor | 54 |
protective effect | 54 |
spinal cord | 54 |
incubation period | 54 |
primary care | 54 |
patients admitted | 54 |
cell types | 54 |
skeletal muscle | 54 |
significant decrease | 54 |
wild type | 53 |
transcription factors | 53 |
pseudomonas aeruginosa | 53 |
trophoblast cells | 53 |
study design | 53 |
respiratory syndrome | 53 |
two different | 53 |
endothelial cell | 53 |
novel coronavirus | 53 |
health systems | 53 |
patients without | 52 |
dose dependent | 52 |
exposed controls | 52 |
mechanically ventilated | 52 |
commonly used | 52 |
preterm birth | 52 |
mm hg | 52 |
ovarian cancer | 52 |
current study | 52 |
tumor cells | 52 |
preterm delivery | 52 |
health system | 51 |
molecular weight | 51 |
ii score | 51 |
kg min | 51 |
cd cd | 51 |
immune responses | 51 |
analysis revealed | 51 |
pulmonary hypertension | 51 |
fold increase | 51 |
analyzed using | 51 |
oxygen species | 50 |
control practices | 50 |
positive correlation | 50 |
study group | 50 |
advisory committee | 50 |
heart failure | 50 |
uric acid | 50 |
differentially expressed | 50 |
respiratory failure | 50 |
optimal controls | 50 |
regression analysis | 50 |
home care | 49 |
menstrual cycle | 49 |
differential diagnosis | 49 |
whole blood | 49 |
total number | 49 |
study aimed | 49 |
organ dysfunction | 49 |
healthy volunteers | 49 |
diabetes mellitus | 48 |
gastrointestinal tract | 48 |
university medical | 48 |
emergency medical | 48 |
inhibitory effect | 48 |
growth restriction | 48 |
cytokine production | 48 |
blood loss | 47 |
blood gases | 47 |
initial conditions | 47 |
new york | 47 |
care workers | 47 |
wound healing | 47 |
th day | 47 |
cancer patients | 47 |
prostate cancer | 47 |
animal models | 47 |
one patient | 47 |
significant correlation | 47 |
enzyme activity | 46 |
human myometrium | 46 |
preterm labor | 46 |
total rna | 46 |
wide range | 46 |
survival rate | 46 |
ffi ffi | 45 |
cell growth | 45 |
hemorrhagic shock | 45 |
pregnant rats | 45 |
patients died | 45 |
pig farmers | 45 |
signaling pathways | 45 |
infection prevention | 45 |
cardiac index | 45 |
binding protein | 45 |
inflammatory cytokines | 45 |
may provide | 45 |
respiratory distress | 44 |
virus infection | 44 |
control activities | 44 |
tnf production | 44 |
muscle cells | 44 |
study period | 44 |
umbilical cord | 44 |
molecular mechanisms | 44 |
weight loss | 44 |
dawley rats | 44 |
healthy controls | 44 |
care facility | 43 |
growth factors | 43 |
university hospital | 43 |
data indicate | 43 |
based precautions | 43 |
statistical significance | 43 |
acute pancreatitis | 43 |
electron microscopy | 43 |
high mortality | 43 |
control theory | 43 |
commercially available | 43 |
bloodstream infections | 42 |
personal protective | 42 |
term care | 42 |
weeks gestation | 42 |
cesarean section | 42 |
patients received | 42 |
control study | 42 |
fetal membranes | 42 |
colorectal cancer | 42 |
gas exchange | 42 |
infected mice | 42 |
three different | 41 |
health emergency | 41 |
immune cells | 41 |
total protein | 41 |
informed consent | 41 |
central nervous | 41 |
air samples | 41 |
free radical | 41 |
animal model | 41 |
expression level | 40 |
different types | 40 |
seir model | 40 |
two patients | 40 |
previously reported | 40 |
small intestine | 40 |
control practice | 40 |
control mechanism | 40 |
hemorrhagic fever | 40 |
increased levels | 40 |
low levels | 40 |
recent years | 40 |
fatty acids | 40 |
cohort study | 40 |
cell cultures | 40 |
aedes aegypti | 40 |
cell migration | 40 |
cell adhesion | 40 |
recent studies | 40 |
bl mice | 40 |
inhibitory control | 39 |
controlled trial | 39 |
adult mice | 39 |
time point | 39 |
severe sepsis | 39 |
lactate levels | 39 |
within days | 39 |
direct contact | 39 |
per day | 39 |
emergency management | 39 |
acute myocardial | 39 |
pulmonary vascular | 39 |
also found | 39 |
first hours | 39 |
life cycle | 39 |
signaling pathway | 39 |
superoxide dismutase | 39 |
significantly associated | 39 |
analysis showed | 39 |
see table | 38 |
mean values | 38 |
protective equipment | 38 |
surgical patients | 38 |
increased significantly | 38 |
oxygen saturation | 38 |
mass spectrometry | 38 |
head injury | 38 |
per year | 38 |
coronary artery | 38 |
airway pressure | 38 |
tidal volume | 38 |
mathematical model | 38 |
schistosomiasis control | 38 |
decreased significantly | 37 |
control animals | 37 |
data analysis | 37 |
protein kinase | 37 |
preliminary results | 37 |
tract infections | 37 |
treated cells | 37 |
closely related | 37 |
nk cells | 37 |
one hour | 37 |
scid mice | 37 |
family members | 37 |
joint prevention | 37 |
social interaction | 37 |
cervical ripening | 37 |
monoclonal antibody | 37 |
airborne transmission | 37 |
type ii | 37 |
urinary tract | 37 |
objective functional | 37 |
treated animals | 36 |
mortality rates | 36 |
mathematical models | 36 |
fatty acid | 36 |
receptor antagonist | 36 |
systemic inflammatory | 36 |
increased expression | 36 |
mice may | 36 |
weight gain | 36 |
fetal brain | 36 |
inbred strains | 36 |
conspiracy beliefs | 36 |
days later | 36 |
optimization problem | 36 |
inflammatory mediators | 36 |
clinical disease | 35 |
showed significant | 35 |
body mass | 35 |
control strategy | 35 |
signal transduction | 35 |
dengue fever | 35 |
inflammatory responses | 35 |
plasma membrane | 35 |
critical care | 35 |
significant changes | 35 |
respiratory infections | 35 |
ca i | 35 |
women undergoing | 35 |
npi implementation | 35 |
infection rates | 35 |
medical personnel | 35 |
distress syndrome | 35 |
multiple sclerosis | 35 |
pao fio | 35 |
pig buildings | 35 |
pasteurella multocida | 35 |
upper respiratory | 34 |
hydrogen peroxide | 34 |
control subjects | 34 |
adhesion molecule | 34 |
three patients | 34 |
differential diagnoses | 34 |
follicular fluid | 34 |
significantly elevated | 34 |
blood mononuclear | 34 |
cystic fibrosis | 34 |
gel electrophoresis | 34 |
plasma concentrations | 34 |
oxygen delivery | 34 |
early pregnancy | 34 |
proinflammatory cytokines | 34 |
lung cancer | 34 |
type diabetes | 34 |
may help | 34 |
contact precautions | 34 |
time rt | 34 |
early stage | 33 |
blood cells | 33 |
sample size | 33 |
reperfusion injury | 33 |
immunocompetent mice | 33 |
coronavirus disease | 33 |
folic acid | 33 |
author funder | 33 |
left ventricular | 33 |
culture media | 33 |
molecular biology | 33 |
clinical course | 33 |
well known | 33 |
control problems | 33 |
white matter | 33 |
negative correlation | 33 |
blood transfusion | 33 |
drug resistance | 33 |
control system | 33 |
granted medrxiv | 33 |
sepsis syndrome | 33 |
control policy | 33 |
serum samples | 33 |
healthy subjects | 33 |
naturally occurring | 33 |
malaria control | 33 |
maximum principle | 33 |
year period | 33 |
conspiracy theory | 32 |
results demonstrate | 32 |
oxygen consumption | 32 |
cd cells | 32 |
health services | 32 |
positive cells | 32 |
infected people | 32 |
way anova | 32 |
mass index | 32 |
immunosorbent assay | 32 |
significant change | 32 |
drinking water | 32 |
may develop | 32 |
time points | 32 |
systemic vascular | 32 |
free radicals | 32 |
major role | 32 |
high fat | 32 |
prevent transmission | 32 |
copyright holder | 32 |
neural network | 32 |
treatment group | 31 |
biological activity | 31 |
cost function | 31 |
sir model | 31 |
antioxidant status | 31 |
terminal time | 31 |
protein level | 31 |
transmission dynamics | 31 |
hong kong | 31 |
major cause | 31 |
protein synthesis | 31 |
short term | 31 |
reactive protein | 31 |
mean sd | 31 |
wistar rats | 31 |
xanthine oxidase | 31 |
least one | 31 |
skin lesions | 31 |
respiratory system | 31 |
group iii | 31 |
blood volume | 31 |
brain injury | 31 |
ventilated patients | 31 |
infectious agent | 31 |
studies suggest | 31 |
thermal injury | 31 |
acute care | 31 |
respiratory protection | 31 |
patients receiving | 31 |
host defense | 31 |
may represent | 31 |
body fluids | 31 |
associated pneumonia | 31 |
significantly greater | 31 |
times higher | 31 |
mouse model | 31 |
tyrosine kinase | 30 |
mouse strains | 30 |
dengue control | 30 |
vaccine effectiveness | 30 |
ang ii | 30 |
breast milk | 30 |
large number | 30 |
visceral leishmaniasis | 30 |
infection rate | 30 |
levels increased | 30 |
i i | 30 |
gram negative | 30 |
version posted | 30 |
control program | 30 |
blood glucose | 30 |
taken together | 30 |
also may | 30 |
data show | 30 |
respiratory syncytial | 30 |
bile duct | 30 |
pandemic influenza | 30 |
state variables | 30 |
care system | 30 |
high dose | 30 |
liver failure | 30 |
normal pregnancy | 30 |
may result | 30 |
smallpox vaccination | 30 |
experimental groups | 30 |
human endometrial | 30 |
study included | 30 |
response inhibition | 30 |
protective effects | 29 |
eoc cells | 29 |
disease transmission | 29 |
palliative care | 29 |
infected population | 29 |
early diagnosis | 29 |
susceptible population | 29 |
receptor expression | 29 |
among patients | 29 |
cancer therapy | 29 |
lawsonia intracellularis | 29 |
antimicrobial agents | 29 |
glioma cells | 29 |
close contact | 29 |
drug administration | 29 |
postoperative period | 29 |
medical school | 29 |
health workers | 29 |
chronic disease | 29 |
blood cultures | 29 |
hospital stay | 29 |
systematic review | 29 |
group compared | 29 |
stromal cells | 29 |
enzyme activities | 29 |
oc problem | 29 |
linked immunosorbent | 28 |
tumor growth | 28 |
human population | 28 |
class i | 28 |
model system | 28 |
decidual cells | 28 |
fetal plasma | 28 |
ms ms | 28 |
dna methylation | 28 |
also showed | 28 |
adverse effects | 28 |
fold higher | 28 |
low birth | 28 |
results obtained | 28 |
innate immune | 28 |
copd patients | 28 |
previously shown | 28 |
studies showed | 28 |
genomic dna | 28 |
maternal plasma | 28 |
zealand white | 28 |
cell survival | 28 |
granulosa cells | 28 |
human endometrium | 28 |
secretory phase | 28 |
infected animals | 28 |
also known | 28 |
influenza vaccination | 28 |
important roles | 28 |
pressure support | 28 |
mast cells | 28 |
key role | 28 |
bacterial translocation | 28 |
target genes | 28 |
respiratory viruses | 28 |
cytotoxic effect | 28 |
evaluated using | 28 |
significant association | 28 |
syncytial virus | 27 |
significantly correlated | 27 |
time course | 27 |
environmental contamination | 27 |
peritoneal macrophages | 27 |
expression pattern | 27 |
tissue injury | 27 |
biochemical parameters | 27 |
respiratory infection | 27 |
three days | 27 |
growth hormone | 27 |
study showed | 27 |
acute renal | 27 |
sensitivity analysis | 27 |
studied patients | 27 |
standard deviation | 27 |
ebola virus | 27 |
portal vein | 27 |
laboratory rabbits | 27 |
borne diseases | 27 |
critical role | 27 |
environmental cleaning | 27 |
villous explants | 27 |
fat diet | 27 |
days post | 27 |
patients treated | 27 |
communicable diseases | 27 |
control efforts | 27 |
cancer stem | 27 |
dengue infection | 27 |
five patients | 27 |
ad libitum | 27 |
umbilical vein | 27 |
age groups | 27 |
tissue damage | 27 |
high level | 27 |
glucose levels | 27 |
necessary conditions | 27 |
quantitative rt | 27 |
venous pressure | 27 |
maternal age | 27 |
first day | 26 |
colon cancer | 26 |
developed countries | 26 |
red blood | 26 |
lbsapsal group | 26 |
among women | 26 |
fatality rate | 26 |
oxide synthase | 26 |
septic complications | 26 |
ejection fraction | 26 |
bloodstream infection | 26 |
salivary glands | 26 |
multiple trauma | 26 |
semiformal organizations | 26 |
age years | 26 |
blood vessels | 26 |
fetal sheep | 26 |
plasma volume | 26 |
general population | 26 |
high concentrations | 26 |
bacterial infections | 26 |
three times | 26 |
clinical trial | 26 |
negative bacteria | 26 |
crucial role | 26 |
nasopharynx samples | 26 |
lutzomyia longipalpis | 26 |
inbred strain | 26 |
two hours | 26 |
vascular endothelial | 26 |
beneficial effects | 26 |
rat model | 26 |
total body | 26 |
laboratory mouse | 26 |
blood gas | 26 |
athymic mice | 26 |
rural areas | 26 |
mammalian cells | 26 |
two types | 26 |
may affect | 26 |
case fatality | 26 |
kg body | 26 |
matrix metalloproteinases | 26 |
control cells | 26 |
even though | 26 |
synthetic biology | 26 |
culture medium | 26 |
equilibrium point | 26 |
may explain | 26 |
ug ml | 26 |
glucose tolerance | 26 |
heat shock | 26 |
health problem | 26 |
first days | 25 |
leading cause | 25 |
total antioxidant | 25 |
one case | 25 |
onset preeclampsia | 25 |
negative controls | 25 |
associated infections | 25 |
cardiac arrest | 25 |
liver tissue | 25 |
control mechanisms | 25 |
liver function | 25 |
burn injury | 25 |
caesarean section | 25 |
severe ards | 25 |
resistant enterococci | 25 |
human myometrial | 25 |
nosocomial transmission | 25 |
low concentrations | 25 |
antibiotic therapy | 25 |
female mice | 25 |
intrauterine growth | 25 |
human placenta | 25 |
pulmonary embolism | 25 |
brain tissue | 25 |
matched controls | 25 |
four groups | 25 |
ischemia reperfusion | 25 |
antioxidant capacity | 25 |
normal pregnancies | 25 |
randomised controlled | 25 |
confocal microscopy | 25 |
influenza vaccine | 25 |
cardiogenic shock | 25 |
hours later | 25 |
mice infected | 25 |
normal range | 25 |
tumor volume | 25 |
antibiotic treatment | 25 |
myxoma virus | 25 |
linear regression | 25 |
influenza virus | 25 |
ampk complex | 25 |
age group | 25 |
health authorities | 25 |
consecutive patients | 25 |
treatment groups | 25 |
made available | 25 |
respiratory disease | 25 |
nasopharyngeal flora | 25 |
immunization practices | 24 |
patients suffering | 24 |
retrospective study | 24 |
late gestation | 24 |
assessed using | 24 |
contact tracing | 24 |
dna synthesis | 24 |
connective tissue | 24 |
play important | 24 |
tissue samples | 24 |
pneumocystis carinii | 24 |
wide variety | 24 |
natural infection | 24 |
disease prevention | 24 |
artery catheter | 24 |
diabetic patients | 24 |
postoperative day | 24 |
high incidence | 24 |
mixed venous | 24 |
new cases | 24 |
fetal weight | 24 |
dengue virus | 24 |
trophoblast cell | 24 |
also increased | 24 |
investigate whether | 24 |
obstetrics gynecology | 24 |
mouse colonies | 24 |
low dose | 24 |
cell activation | 24 |
genes involved | 24 |
mycobacterium tuberculosis | 24 |
liquid chromatography | 24 |
better understanding | 24 |
antimicrobial activity | 24 |
cytokine levels | 24 |
herpes simplex | 24 |
mitochondrial membrane | 24 |
universal precautions | 24 |
low control | 24 |
los angeles | 24 |
major surgery | 24 |
gnrh ii | 23 |
icu stay | 23 |
cells treated | 23 |
mouse strain | 23 |
high affinity | 23 |
mg protein | 23 |
medical care | 23 |
nursing homes | 23 |
blood culture | 23 |
infant mice | 23 |
jugular bulb | 23 |
antibiotic resistance | 23 |
also significantly | 23 |
pg kg | 23 |
blood lactate | 23 |
year old | 23 |
hemodynamic parameters | 23 |
well tolerated | 23 |
high frequency | 23 |
mesenteric lymph | 23 |
human mobility | 23 |
saps ii | 23 |
first study | 23 |
aea levels | 23 |
laboratory animals | 23 |
treated rats | 23 |
fetal lung | 23 |
optimal strategy | 23 |
optimal solution | 23 |
many studies | 23 |
persistent pulmonary | 23 |
platelet activation | 23 |
normal human | 23 |
tumor cell | 23 |
semiformal control | 23 |
newborn offspring | 23 |
animal studies | 23 |
control policies | 23 |
patients showed | 23 |
tissue sections | 23 |
tumor suppressor | 23 |
white blood | 23 |
class ii | 23 |
preventing transmission | 23 |
environmental factors | 23 |
remained unchanged | 23 |
nuclear factor | 23 |
bile acid | 23 |
cerebrospinal fluid | 23 |
investigated whether | 23 |
progenitor cells | 23 |
toxic effects | 23 |
constant control | 23 |
following trauma | 23 |
data collection | 23 |
severe head | 23 |
different doses | 22 |
heart surgery | 22 |
also observed | 22 |
significantly less | 22 |
parameter values | 22 |
nursing home | 22 |
within minutes | 22 |
infected rabbits | 22 |
ordinary differential | 22 |
control mice | 22 |
recovery rate | 22 |
last years | 22 |
jugular vein | 22 |
group showed | 22 |
genetically engineered | 22 |
experimental studies | 22 |
exact test | 22 |
university school | 22 |
disease caused | 22 |
transforming growth | 22 |
steady state | 22 |
infected patients | 22 |
ace activity | 22 |
large numbers | 22 |
male wistar | 22 |
bile acids | 22 |
i min | 22 |
also used | 22 |
rating scale | 22 |
predictive value | 22 |
cytotoxic effects | 22 |
blood levels | 22 |
one week | 22 |
compared using | 22 |
beneficial effect | 22 |
cardiovascular disease | 22 |
positive control | 22 |
viral infections | 22 |
mean sem | 22 |
healthy individuals | 22 |
study groups | 22 |
mesenchymal stem | 22 |
control charts | 22 |
ethics committee | 22 |
apoptotic cell | 22 |
respiratory secretions | 22 |
oxygen radicals | 22 |
blood cell | 22 |
parasite load | 22 |
evidence suggests | 22 |
artery pressure | 21 |
cd expression | 21 |
throughout pregnancy | 21 |
social interactions | 21 |
femoral artery | 21 |
glucose uptake | 21 |
treated group | 21 |
infection may | 21 |
polycystic ovary | 21 |
right ventricular | 21 |
international license | 21 |
naturally infected | 21 |
cell population | 21 |
infected humans | 21 |
one month | 21 |
person transmission | 21 |
surveillance system | 21 |
infected subjects | 21 |
cells compared | 21 |
marked increase | 21 |
confirmed cases | 21 |
placental tissue | 21 |
four different | 21 |
potential role | 21 |
science foundation | 21 |
membrane potential | 21 |
airborne precautions | 21 |
human fetal | 21 |
hospital infection | 21 |
despite enhanced | 21 |
one study | 21 |
may increase | 21 |
pelvic organ | 21 |
total population | 21 |
data demonstrate | 21 |
significantly inhibited | 21 |
maternal blood | 21 |
differential expression | 21 |
neonatal outcome | 21 |
emergency department | 21 |
data showed | 21 |
cord blood | 21 |
differ significantly | 21 |
statistically different | 21 |
respiratory rate | 21 |
uterine emg | 21 |
abdominal sepsis | 21 |
acid use | 21 |
method using | 21 |
poorly understood | 21 |
leydig cells | 21 |
pd patients | 21 |
six patients | 21 |
human health | 21 |
respiratory virus | 21 |
heart disease | 21 |
binding sites | 21 |
high doses | 21 |
poor prognosis | 21 |
mtt assay | 21 |
inflammatory reaction | 21 |
considered significant | 21 |
liver transplantation | 21 |
tract infection | 21 |
care setting | 21 |
rabies control | 21 |
immune function | 21 |
per group | 21 |
es cells | 21 |
lower respiratory | 21 |
phase i | 21 |
one hundred | 21 |
persistent infection | 21 |
miu ml | 21 |
surface area | 21 |
experimental animals | 21 |
control rats | 21 |
every hours | 21 |
ten patients | 21 |
clinical outcome | 21 |
exposed individuals | 21 |
positively correlated | 21 |
cancer treatment | 21 |
clinical studies | 21 |
ml vs | 21 |
normal subjects | 21 |
objective function | 20 |
analysis using | 20 |
eye protection | 20 |
dna binding | 20 |
college students | 20 |
group received | 20 |
myocardial ischemia | 20 |
ischemic stroke | 20 |
luteal cells | 20 |
mda levels | 20 |
systolic blood | 20 |
studies using | 20 |
practices advisory | 20 |
pregnancy outcome | 20 |
russian science | 20 |
sexually transmitted | 20 |
peer review | 20 |
negative bacilli | 20 |
negative sepsis | 20 |
single dose | 20 |
endotracheal tube | 20 |
different levels | 20 |
insulin levels | 20 |
single nucleotide | 20 |
pediatric patients | 20 |
effective treatment | 20 |
median age | 20 |
oxygen tension | 20 |
vascular smooth | 20 |
west africa | 20 |
odds ratio | 20 |
inflammatory cells | 20 |
resistant organisms | 20 |
mhc class | 20 |
significant role | 20 |
general anesthesia | 20 |
meconium passage | 20 |
female college | 20 |
pharmacists prescribing | 20 |
medical university | 20 |
plasma samples | 20 |
human bocavirus | 20 |
recombinant human | 20 |
preliminary data | 20 |
treatment strategies | 20 |
capillaria hepatica | 20 |
ic values | 20 |
host response | 20 |
ovary syndrome | 20 |
gene therapy | 20 |
relatively high | 20 |
patients requiring | 20 |
organ injury | 20 |
possible role | 20 |
middle east | 20 |
glutathione peroxidase | 20 |
following parameters | 20 |
cough etiquette | 20 |
hygiene compliance | 20 |
study suggests | 20 |
prospectively studied | 20 |
severity score | 20 |
local governments | 20 |
immunodeficiency virus | 20 |
blood transfusions | 20 |
health service | 20 |
pathway controls | 20 |
asthma control | 20 |
peritoneal cavity | 20 |
study shows | 20 |
randomly divided | 20 |
time interval | 20 |
future studies | 20 |
similar results | 20 |
white rabbits | 20 |
normal values | 20 |
cape verde | 20 |
virus infections | 20 |
serum il | 20 |
low level | 20 |
eradication time | 19 |
research council | 19 |
control programmes | 19 |
perinatal outcomes | 19 |
lactation period | 19 |
oral glucose | 19 |
directed behaviors | 19 |
case finding | 19 |
reproductive sciences | 19 |
elevated levels | 19 |
significantly improved | 19 |
control programme | 19 |
american neurological | 19 |
two days | 19 |
central role | 19 |
plasma endotoxin | 19 |
two weeks | 19 |
experimentally infected | 19 |
renal function | 19 |
patient safety | 19 |
posted april | 19 |
acute lung | 19 |
low molecular | 19 |
average number | 19 |
cellular immune | 19 |
increasing concentrations | 19 |
helicobacter hepaticus | 19 |
viral infection | 19 |
preterm labour | 19 |
function tests | 19 |
using specific | 19 |
diarrheal diseases | 19 |
significant effect | 19 |
organ damage | 19 |
apoptotic cells | 19 |
results demonstrated | 19 |
neurological association | 19 |
training group | 19 |
pregnancies complicated | 19 |
droplet precautions | 19 |
response syndrome | 19 |
placental abruption | 19 |
oryctolagus cuniculus | 19 |
occupational safety | 19 |
tnf levels | 19 |
human placental | 19 |
paraffin embedded | 19 |
shear stress | 19 |
antioxidant activity | 19 |
lung tissue | 19 |
ards patients | 19 |
herd immunity | 19 |
pulmonary edema | 19 |
organ system | 19 |
fetal dna | 19 |
control values | 19 |
government agencies | 19 |
cerebral blood | 19 |
early stages | 19 |
patients may | 19 |
plasma aea | 19 |
death rate | 19 |
clinically relevant | 19 |
simplex virus | 19 |
hospitalized patients | 19 |
marginal contribution | 19 |
cell type | 19 |
control variable | 19 |
influenza pandemic | 19 |
may indicate | 19 |
carotid artery | 19 |
nursing staff | 19 |
epidemiological models | 19 |
treated patients | 19 |
risk groups | 19 |
human immunodeficiency | 19 |
total oxidant | 19 |
time dependent | 19 |
genes encoding | 19 |
deficient mice | 19 |
parenteral nutrition | 19 |
research institute | 19 |
optimal trading | 19 |
vitro studies | 19 |
microbiology laboratory | 19 |
elective cesarean | 19 |
cell function | 19 |
hours following | 19 |
present work | 19 |
susceptible individuals | 19 |
cardiovascular diseases | 19 |
previously described | 19 |
pilot study | 19 |
oxidant status | 19 |
rats received | 19 |
elderly patients | 19 |
pivotal role | 19 |
time period | 19 |
guinea pigs | 19 |
receptor mrna | 19 |
urban areas | 19 |
north america | 19 |
care providers | 19 |
cumulative deaths | 19 |
demographic data | 19 |
equilibrium points | 19 |
confidence interval | 19 |
well established | 18 |
large amounts | 18 |
rat liver | 18 |
pregnant mice | 18 |
fetal heart | 18 |
diagnosis diagnosis | 18 |
cardiac function | 18 |
also determined | 18 |
converting enzyme | 18 |
may include | 18 |
helicobacter spp | 18 |
crp levels | 18 |
risky decision | 18 |
amh levels | 18 |
cell count | 18 |
shed blood | 18 |
neonatal outcomes | 18 |
motor neuron | 18 |
adult patients | 18 |
south america | 18 |
ovulation induction | 18 |
seven patients | 18 |
transplant recipients | 18 |
klebsiella pneumoniae | 18 |
dynamic optimization | 18 |
risk patients | 18 |
ng kg | 18 |
mass vaccination | 18 |
normal controls | 18 |
vaccination process | 18 |
proliferative phase | 18 |
several studies | 18 |
will also | 18 |
expression profiles | 18 |
drug delivery | 18 |
gestational diabetes | 18 |
reproductive tract | 18 |
jakob disease | 18 |
experimental model | 18 |
scoring system | 18 |
using elisa | 18 |
brain death | 18 |
studies indicate | 18 |
pcr assays | 18 |
clinical diagnosis | 18 |
health interventions | 18 |
human umbilical | 18 |
stimulating factor | 18 |
disease outbreaks | 18 |
latin america | 18 |
near term | 18 |
adverse events | 18 |
chi square | 18 |
different concentrations | 18 |
oxygen extraction | 18 |
lactate dehydrogenase | 18 |
ringo spy | 18 |
intravenous infusion | 18 |
epidemic models | 18 |
domestic rabbits | 18 |
ad patients | 18 |
injury severity | 18 |
molecular dynamics | 18 |
lower levels | 18 |
underlying disease | 18 |
experimental infection | 18 |
using standard | 18 |
pcr analysis | 18 |
mast cell | 18 |
human uterine | 18 |
hepatocellular carcinoma | 18 |
positive blood | 18 |
endemic areas | 18 |
circulating levels | 18 |
intravascular coagulation | 18 |
laboratory tests | 18 |
longipalpis salivary | 18 |
fluorescence microscopy | 18 |
disseminated intravascular | 18 |
ct scan | 18 |
risk task | 18 |
decision making | 18 |
inclusion criteria | 18 |
inflammatory process | 18 |
infection surveillance | 18 |
data obtained | 18 |
lps challenge | 18 |
terminal domain | 18 |
bronchoalveolar lavage | 18 |
initial value | 18 |
natural enemies | 17 |
i levels | 17 |
amyotrophic lateral | 17 |
regression model | 17 |
mechanisms underlying | 17 |
binding proteins | 17 |
vaccination program | 17 |
cecal ligation | 17 |
body temperature | 17 |
leading group | 17 |
enteral nutrition | 17 |
every day | 17 |
following treatment | 17 |
medical centre | 17 |
interaction control | 17 |
pregnancy outcomes | 17 |
lateral sclerosis | 17 |
uterine contractions | 17 |
stress response | 17 |
will help | 17 |
bowel disease | 17 |
probably due | 17 |
may reduce | 17 |
mrna level | 17 |
breathing pattern | 17 |
domestic animals | 17 |
optimal solutions | 17 |
male mice | 17 |
tissue oxygenation | 17 |
several weeks | 17 |
endometrial cancer | 17 |
occupational exposure | 17 |
first step | 17 |
resistant bacteria | 17 |
albino rats | 17 |
common cause | 17 |
crime control | 17 |
burned patients | 17 |
viral disease | 17 |
therapeutic agents | 17 |
risk assessment | 17 |
obese women | 17 |
national nosocomial | 17 |
soft tissue | 17 |
resistance genes | 17 |
quantitative real | 17 |
di giacomo | 17 |
organ prolapse | 17 |
correlation analysis | 17 |
dna samples | 17 |
case study | 17 |
phase ii | 17 |
abdominal surgery | 17 |
lipid peroxide | 17 |
hyaluronic acid | 17 |
platelet count | 17 |
may reflect | 17 |
surgical procedures | 17 |
serum albumin | 17 |
ankara university | 17 |
autologous blood | 17 |
administration cost | 17 |
scanning electron | 17 |
pharmaceutical interventions | 17 |
transgenic mice | 17 |
lung disease | 17 |
cultured cells | 17 |
intestinal tract | 17 |
total thiol | 17 |
like receptors | 17 |
chronic inflammatory | 17 |
myometrial cells | 17 |
effective control | 17 |
smallpox virus | 17 |
new behaviors | 17 |
results indicated | 17 |
patients underwent | 17 |
male offspring | 17 |
icu admission | 17 |
vascular tone | 17 |
working group | 17 |
uterine artery | 17 |
progesterone receptor | 17 |
asthma patients | 17 |
full dose | 17 |
isolated using | 17 |
included patients | 17 |
young children | 17 |
plasma glucose | 17 |
square test | 17 |
sprague dawley | 17 |
core control | 17 |
affected animals | 17 |
research center | 17 |
one year | 17 |
oxidative damage | 17 |
mean value | 17 |
clinical microbiology | 17 |
cells may | 17 |
highly significant | 17 |
final time | 17 |
vaccinia virus | 17 |
many countries | 17 |
whole genome | 17 |
women without | 17 |
dna repair | 17 |
diabetic rats | 17 |
inhibitory effects | 17 |
also measured | 17 |
endothelial growth | 17 |
prone position | 17 |
also studied | 17 |
proliferative enteropathy | 17 |
enteral feeding | 17 |
pig farmer | 17 |
preeclamptic women | 17 |
dengue transmission | 17 |
human rabies | 17 |
human pregnancy | 17 |
prescribing birth | 17 |
qs qt | 17 |
control model | 17 |
body surface | 17 |
related genes | 17 |
defense mechanisms | 17 |
mouse populations | 17 |
adjoint variables | 17 |
community workers | 17 |
bacterial infection | 16 |
cancer chemotherapy | 16 |
survival time | 16 |
lymphocyte ratio | 16 |
artery bypass | 16 |
data mining | 16 |
normal weight | 16 |
wistar albino | 16 |
endotracheal intubation | 16 |
fetal body | 16 |
dna polymerase | 16 |
test results | 16 |
hours post | 16 |
limited resources | 16 |
significant improvement | 16 |
surgical trauma | 16 |
promoter activity | 16 |
critical illness | 16 |
next generation | 16 |
travel restriction | 16 |
active site | 16 |
conducted using | 16 |
granulosa cell | 16 |
optimality system | 16 |
rcd virus | 16 |
inflammatory cytokine | 16 |
chronic diseases | 16 |
data suggests | 16 |
haemorrhagic disease | 16 |
factor alpha | 16 |
adult respiratory | 16 |
stress conditions | 16 |
growth rate | 16 |
hiv infection | 16 |
human serum | 16 |
state system | 16 |
may influence | 16 |
promoter region | 16 |
hiv aids | 16 |
healthy control | 16 |
wedge pressure | 16 |
infected individual | 16 |
radical scavenging | 16 |
early phase | 16 |
culture conditions | 16 |
oocyte maturation | 16 |
cellular immunity | 16 |
days following | 16 |
informal caregivers | 16 |
blood products | 16 |
singular arc | 16 |
world bank | 16 |
study population | 16 |
patients following | 16 |
endometrial stromal | 16 |
dengue prevention | 16 |
parameter estimation | 16 |
activated protein | 16 |
placental villous | 16 |
enzymatic activity | 16 |
canine visceral | 16 |
previous study | 16 |
also performed | 16 |
epidemic model | 16 |
remains unclear | 16 |
high control | 16 |
per patient | 16 |
carrying capacity | 16 |
respiratory hygiene | 16 |
yellow fever | 16 |
least days | 16 |
treated mice | 16 |
hospital mortality | 16 |
calculated using | 16 |
days lost | 16 |
partial hepatectomy | 16 |
estrogen receptor | 16 |
myeloid leukemia | 16 |
therapeutic approach | 16 |
severe preeclampsia | 16 |
industrialized countries | 16 |
response efforts | 16 |
affinity chromatography | 16 |
right heart | 16 |
inflammatory processes | 16 |
using different | 16 |
prolonged periods | 16 |
increased compared | 16 |
different control | 16 |
spontaneous breathing | 16 |
trait self | 16 |
induced apoptosis | 16 |
hepatic failure | 16 |
uterine smooth | 16 |
neonatal mice | 16 |
done using | 16 |
myogenic reactivity | 16 |
previously demonstrated | 16 |
tissue culture | 16 |
nine patients | 16 |
initial number | 16 |
placental insufficiency | 16 |
acquired infections | 16 |
epidemiological control | 16 |
medical treatment | 16 |
expressed genes | 16 |
transversality conditions | 16 |
care patients | 16 |
higher incidence | 16 |
severe trauma | 16 |
also evaluated | 16 |
care delivery | 16 |
complement system | 16 |
countries regions | 16 |
cell membrane | 16 |
artery catheters | 16 |
small number | 16 |
renal dysfunction | 16 |
nucleic acid | 16 |
differential system | 16 |
acute liver | 16 |
among children | 16 |
one health | 16 |
health sciences | 16 |
obtained results | 16 |
respiratory insufficiency | 16 |
vaginal delivery | 16 |
cell wall | 15 |
granulocyte colony | 15 |
alternative splicing | 15 |
dengue epidemics | 15 |
epidermal growth | 15 |
phase proteins | 15 |
cultured human | 15 |
clinical data | 15 |
inhibitory activity | 15 |
learned controls | 15 |
subclinical hypothyroidism | 15 |
rabies elimination | 15 |
energy expenditure | 15 |
ucla med | 15 |
cell division | 15 |
healthy women | 15 |
three months | 15 |
patient group | 15 |
genome sequence | 15 |
biological activities | 15 |
specific antibodies | 15 |
randomly selected | 15 |
lps injection | 15 |
occupational health | 15 |
maternal food | 15 |
cost functional | 15 |
per hour | 15 |
source control | 15 |
cellular processes | 15 |
family history | 15 |
reported cases | 15 |
control patients | 15 |
newly diagnosed | 15 |
disease free | 15 |
venous catheters | 15 |
angiogenic factors | 15 |
young adults | 15 |
induced preterm | 15 |
expression may | 15 |
ferulic acid | 15 |
colony formation | 15 |
effect size | 15 |
mucous membranes | 15 |
induced oxidative | 15 |
general health | 15 |
boric acid | 15 |
infectious particles | 15 |
differential equation | 15 |
samples obtained | 15 |
wastewater workers | 15 |
evoked potentials | 15 |
national institute | 15 |
experimental inoculation | 15 |
prostaglandin synthesis | 15 |
cytokine release | 15 |
technical university | 15 |
two times | 15 |
two methods | 15 |
patient populations | 15 |
health departments | 15 |
pancreatic duct | 15 |
nerve fibers | 15 |
pcr assay | 15 |
system failure | 15 |
mus musculus | 15 |
investigated using | 15 |
negative control | 15 |
lesser extent | 15 |
saharan africa | 15 |
transmitted diseases | 15 |
levels decreased | 15 |
nosocomial pneumonia | 15 |
patient contact | 15 |
peroxide levels | 15 |
multivariate analysis | 15 |
one another | 15 |
infectious burden | 15 |
tissue hypoxia | 15 |
deleterious effects | 15 |
nutritional status | 15 |
quantitative analysis | 15 |
rat brain | 15 |
maternal serum | 15 |
droplet nuclei | 15 |
health facilities | 15 |
high prevalence | 15 |
first report | 15 |
higher risk | 15 |
infectious individuals | 15 |
surgical masks | 15 |
resistin levels | 15 |
many tissues | 15 |
control interventions | 15 |
may serve | 15 |
showed increased | 15 |
swine influenza | 15 |
fusion protein | 15 |
candidate genes | 15 |
inbred mice | 15 |
infants born | 15 |
balloon analog | 15 |
transit time | 15 |
glioma cell | 15 |
waist circumference | 15 |
change significantly | 15 |
clinical symptoms | 15 |
increasing doses | 15 |
first two | 15 |
see chapter | 15 |
umbilical artery | 15 |
observation period | 15 |
two cases | 15 |
findings indicate | 15 |
white cell | 15 |
essential oil | 15 |
cardiopulmonary bypass | 15 |
flow cytometric | 15 |
bile ducts | 15 |
cycle arrest | 15 |
ganoderma lucidum | 15 |
spontaneous contractions | 15 |
patient groups | 15 |
retrospective cohort | 15 |
squamous cell | 15 |
ganz catheter | 15 |
surgical icu | 15 |
cells using | 15 |
well plates | 15 |
levels may | 15 |
april th | 15 |
month period | 15 |
surgical treatment | 15 |
therapeutic strategies | 15 |
medical history | 15 |
adverse outcomes | 15 |
last two | 15 |
serratia marcescens | 15 |
mean blood | 15 |
significant negative | 15 |
cell differentiation | 15 |
analog risk | 15 |
randomly assigned | 15 |
hcg levels | 15 |
identified using | 15 |
emergency response | 15 |
luteal phase | 15 |
endometrial cells | 15 |
receive either | 15 |
real data | 15 |
ex vivo | 15 |
common bile | 15 |
microscopic examination | 15 |
epidemic duration | 15 |
personal control | 15 |
group consisted | 15 |
may offer | 15 |
case report | 15 |
hormone levels | 15 |
endoplasmic reticulum | 15 |
medical students | 15 |
pcr using | 15 |
intersectoral collaboration | 15 |
kg bw | 15 |
turkey introduction | 15 |
currently available | 15 |
rat placenta | 15 |
cell infiltration | 15 |
exposed population | 15 |
days gestation | 14 |
cmv infection | 14 |
smallpox vaccine | 14 |
performance liquid | 14 |
general hospital | 14 |
major abdominal | 14 |
studies demonstrated | 14 |
vivo studies | 14 |
initial condition | 14 |
genetically modified | 14 |
oxygen free | 14 |
operations center | 14 |
disease progression | 14 |
important factors | 14 |
patients whose | 14 |
transmission risks | 14 |
rabbit populations | 14 |
murine model | 14 |
cytokine expression | 14 |
early gestation | 14 |
human pathogens | 14 |
community health | 14 |
blood count | 14 |
tissue engineering | 14 |
premature rupture | 14 |
control banding | 14 |
iugr newborns | 14 |
theory beliefs | 14 |
reproductive number | 14 |
placental tissues | 14 |
provide evidence | 14 |
comet assay | 14 |
mathematical modeling | 14 |
trend towards | 14 |
staff members | 14 |
lymphoid tissue | 14 |
genetic variation | 14 |
recombinant protein | 14 |
expression analysis | 14 |
severe disease | 14 |
transmission occurs | 14 |
transgenic rabbit | 14 |
patients required | 14 |
community engagement | 14 |
random graph | 14 |
southeast asia | 14 |
sepsis score | 14 |
correlation coefficient | 14 |
response rate | 14 |
burn wound | 14 |
expression vector | 14 |
mesenteric artery | 14 |
rats subjected | 14 |
density lipoprotein | 14 |
blood serum | 14 |
positive effect | 14 |
virus type | 14 |
causative agent | 14 |
economic output | 14 |
unk cells | 14 |
delayed control | 14 |
salmonella spp | 14 |
cytotoxic activity | 14 |
noninfluenza respiratory | 14 |
tnf receptor | 14 |
cells express | 14 |
initial values | 14 |
second trimester | 14 |
first week | 14 |
polyclonal antibodies | 14 |
blood coagulation | 14 |
ml respectively | 14 |
protective role | 14 |
average age | 14 |
surgical intensive | 14 |
factors associated | 14 |
vast majority | 14 |
fat mass | 14 |
brain damage | 14 |
teaching hospital | 14 |
experimental study | 14 |
rights reserved | 14 |
seven days | 14 |
infectious complications | 14 |
gbm cells | 14 |
pathway analysis | 14 |
time spent | 14 |
imperial college | 14 |
clinical practice | 14 |
steroid hormones | 14 |
plasma tnf | 14 |
dengue hemorrhagic | 14 |
health problems | 14 |
transplantable tumors | 14 |
gene promoter | 14 |
million persons | 14 |
lamina propria | 14 |
observations suggest | 14 |
four patients | 14 |
second group | 14 |
hepatic dysfunction | 14 |
immobilization stress | 14 |
adult male | 14 |
better understand | 14 |
compensatory control | 14 |
clinical manifestations | 14 |
bacillus subtilis | 14 |
wild mice | 14 |
adrenal glands | 14 |
within one | 14 |
care hospital | 14 |
non pregnant | 14 |
eight patients | 14 |
bacterial growth | 14 |
modified albumin | 14 |
releasing hormone | 14 |
cancer types | 14 |
fatality rates | 14 |
results revealed | 14 |
neural net | 14 |
vertebrate pests | 14 |
fasting glucose | 14 |
small molecules | 14 |
clinical conditions | 14 |
brain regions | 14 |
study demonstrates | 14 |
health education | 14 |
positive bacteria | 14 |
infections associated | 14 |
switching time | 14 |
communicable disease | 14 |
enhanced newborn | 14 |
infections caused | 14 |
vertical transmission | 14 |
less likely | 14 |
epidemiologically important | 14 |
natural killer | 14 |
protein complexes | 14 |
hours prior | 14 |
liver injury | 14 |
immunocompromised patients | 14 |
ml saline | 14 |
metabolic rate | 14 |
fold lower | 14 |
work groups | 14 |
food restriction | 14 |
organ systems | 14 |
pelvic pain | 14 |
dependent fashion | 14 |
available data | 14 |
experimental models | 14 |
studies show | 14 |
overall survival | 14 |
higher compared | 14 |
abdominal pain | 14 |
one hand | 14 |
pediatric intensive | 14 |
air bronchogram | 14 |
receptor antagonists | 14 |
transcriptional regulation | 14 |
binding site | 14 |
susceptible mice | 14 |
hospital capacity | 14 |
au mgtp | 14 |
emerging infectious | 14 |
antioxidant properties | 14 |
mongrel dogs | 14 |
paraffin sections | 14 |
venous plasma | 14 |
infected persons | 14 |
embryo transfer | 14 |
chronic inflammation | 14 |
jak stat | 14 |
long periods | 14 |
ectromelia virus | 14 |
cesarean delivery | 14 |
cerebral artery | 14 |
angiotensin ii | 14 |
fetal death | 14 |
potential therapeutic | 14 |
joint national | 14 |
pancreatic transplantation | 14 |
degradation products | 14 |
dose rates | 14 |
collagen i | 14 |
continuous infusion | 14 |
clinical use | 14 |
immunohistochemical analysis | 14 |
groups according | 14 |
mainly due | 14 |
energy metabolism | 14 |
guinea pig | 14 |
infection associated | 14 |
independent risk | 14 |
data support | 14 |
normal value | 14 |
bronchogram sign | 14 |
canine rabies | 14 |
serum concentrations | 14 |
surface receptors | 14 |
dengue cases | 14 |
gross lesions | 14 |
therapeutic approaches | 14 |
isolation precautions | 14 |
tertiary care | 14 |
may contain | 14 |
nmol mg | 14 |
dependent increase | 14 |
intravenous injection | 14 |
results support | 14 |
psychological stress | 14 |
old woman | 14 |
positive controls | 14 |
analysis demonstrated | 14 |
protease inhibitors | 14 |
new model | 14 |
data provide | 14 |
suckling mice | 14 |
model parameters | 14 |
highly expressed | 13 |
control functions | 13 |
health emergencies | 13 |
graft survival | 13 |
analysis indicated | 13 |
western analysis | 13 |
eef ba | 13 |
may suggest | 13 |
daily living | 13 |
facs analysis | 13 |
apache iii | 13 |
high self | 13 |
third trimester | 13 |
increased susceptibility | 13 |
natural history | 13 |
litter size | 13 |
infections surveillance | 13 |
mass spectrometer | 13 |
public reporting | 13 |
laboratory testing | 13 |
samples collected | 13 |
pain relief | 13 |
energy charge | 13 |
four hours | 13 |
face shields | 13 |
vascular permeability | 13 |
virulence factors | 13 |
oxygen transport | 13 |
flow rate | 13 |
increased il | 13 |
infectious period | 13 |
mediated immunity | 13 |
relative abundance | 13 |
healthcare infection | 13 |
state variable | 13 |
ic value | 13 |
pancreatic cancer | 13 |
supportive care | 13 |
soluble adhesion | 13 |
metabolic syndrome | 13 |
acid composition | 13 |
severe asthma | 13 |
lps stimulation | 13 |
mouse genome | 13 |
first group | 13 |
patient died | 13 |
mpm ii | 13 |
metabolic alterations | 13 |
mediated immune | 13 |
tos levels | 13 |
epithelial ovarian | 13 |
mean pulmonary | 13 |
software packages | 13 |
mesenteric arteries | 13 |
negative pressure | 13 |
broad spectrum | 13 |
postoperative complications | 13 |
preventive measures | 13 |
kg i | 13 |
two years | 13 |
educational campaigns | 13 |
acid sequence | 13 |
medical branch | 13 |
animals received | 13 |
potentially infectious | 13 |
animal experiments | 13 |
endotoxic shock | 13 |
chest wall | 13 |
ketone body | 13 |
young mice | 13 |
ischemia modified | 13 |
tolerance test | 13 |
studied using | 13 |
liver enzymes | 13 |
antimicrobial therapy | 13 |
patients compared | 13 |
creative commons | 13 |
alternating control | 13 |
different cell | 13 |
hand washing | 13 |
develop new | 13 |
acne vulgaris | 13 |
intracellular ca | 13 |
asymptotically stable | 13 |
four times | 13 |
two months | 13 |
nucleotide polymorphisms | 13 |
strongly suggest | 13 |
interquartile range | 13 |
inflammatory cell | 13 |
drought stress | 13 |
patients studied | 13 |
cell carcinoma | 13 |
environmental surfaces | 13 |
platelet aggregation | 13 |
traumatic injury | 13 |
nk cell | 13 |
acute infection | 13 |
community pharmacy | 13 |
contact system | 13 |
reuse allowed | 13 |
angiotensin converting | 13 |
matrix metalloproteinase | 13 |
clostridium piliforme | 13 |
randomized study | 13 |
bioaerosol exposure | 13 |
four weeks | 13 |
pregnancy rate | 13 |
congenital malformations | 13 |
state council | 13 |
control state | 13 |
mice develop | 13 |
global health | 13 |
inflammatory bowel | 13 |
generating procedures | 13 |
tap beta | 13 |
ultr cells | 13 |
sham operation | 13 |
experimental conditions | 13 |
specific immune | 13 |
pulmonary function | 13 |
quality control | 13 |
hygiene cough | 13 |
placental growth | 13 |
significant relationship | 13 |
reduced expression | 13 |
protein kinases | 13 |
patient population | 13 |
confidence intervals | 13 |
invading cells | 13 |
treatment may | 13 |
combination therapy | 13 |
dna sequences | 13 |
helicobacter species | 13 |
expression profile | 13 |
denv transmission | 13 |
myometrial strips | 13 |
per week | 13 |
difficile infection | 13 |
endothelial dysfunction | 13 |
normal pregnant | 13 |
spleen parasite | 13 |
cells showed | 13 |
tumor microenvironment | 13 |
spectrum beta | 13 |
standard deviations | 13 |
mosquito breeding | 13 |
enteric pathogens | 13 |
clinical presentation | 13 |
acute rejection | 13 |
relatively low | 13 |
analysed using | 13 |
may remain | 13 |
endotoxin levels | 13 |
congestive heart | 13 |
nerve conduction | 13 |
basic reproductive | 13 |
clinical findings | 13 |
odds ratios | 13 |
mainland china | 13 |
fungal infections | 13 |
inhibition training | 13 |
molecular level | 13 |
term pregnant | 13 |
sequence analysis | 13 |
mitochondrial biogenesis | 13 |
response measures | 13 |
virus transmission | 13 |
multiple regression | 13 |
following major | 13 |
induced contractions | 13 |
medical equipment | 13 |
care personnel | 13 |
wound infections | 13 |
salivary gland | 13 |
findings may | 13 |
mesenchymal transition | 13 |
burn patients | 13 |
starting intervention | 13 |
situ hybridization | 13 |
fio ratio | 13 |
statistical analyses | 13 |
control action | 13 |
normal ovaries | 13 |
pcos patients | 13 |
hela cells | 13 |
prenatal exposure | 13 |
old male | 13 |
form solution | 13 |
past years | 13 |
pregnancy rates | 13 |
mathematical modelling | 13 |
induces apoptosis | 13 |
per infusion | 13 |
hh compliance | 13 |
different ways | 13 |
often used | 13 |
allowed without | 13 |
biological systems | 13 |
large scale | 13 |
plasma concentration | 13 |
endemic equilibrium | 13 |
fetal development | 13 |
state university | 13 |
without permission | 13 |
nude mice | 13 |
hospital staff | 13 |
renal arteries | 13 |
kidney transplantation | 13 |
sand fly | 13 |
intervention time | 13 |
rabbit haemorrhagic | 13 |
phenolic compounds | 13 |
right ventricle | 13 |
plasma lactate | 13 |
travel restrictions | 13 |
ivf icsi | 13 |
human peripheral | 13 |
lung function | 13 |
texas medical | 13 |
primary human | 13 |
also present | 13 |
new method | 13 |
epidemiological studies | 13 |
acinetobacter baumannii | 13 |
tracheal pressure | 13 |
patients diagnosed | 13 |
surgical site | 13 |
positive effects | 13 |
population dynamics | 13 |
also shown | 13 |
differential abundance | 13 |
plasma cortisol | 13 |
cells cultured | 13 |
kg iv | 12 |
one ivs | 12 |
following hs | 12 |
specific genes | 12 |
plasma il | 12 |
differences among | 12 |
malaria elimination | 12 |
pulmonary disease | 12 |
trypan blue | 12 |
graft rejection | 12 |
viability assay | 12 |
perinatal outcome | 12 |
arterial ph | 12 |
cell mass | 12 |
induced cytokine | 12 |
new therapeutic | 12 |
heterozygous mice | 12 |
bovine serum | 12 |
first line | 12 |
higher rates | 12 |
bacterial contamination | 12 |
positive results | 12 |
widely distributed | 12 |
respiratory droplets | 12 |
mental health | 12 |
inflammatory diseases | 12 |
saccharomyces cerevisiae | 12 |
numerical methods | 12 |
glucose homeostasis | 12 |
cortisol levels | 12 |
microbial community | 12 |
future work | 12 |
disease severity | 12 |
humoral immunity | 12 |
fetal inflammatory | 12 |
medical intensive | 12 |
american academy | 12 |
obese patients | 12 |
safety culture | 12 |
mean duration | 12 |
chronically ill | 12 |
mtor signaling | 12 |
placebo group | 12 |
saddle point | 12 |
low doses | 12 |
medium supplemented | 12 |
controlled study | 12 |
oxygen supply | 12 |
artery disease | 12 |
virus disease | 12 |
rabbit model | 12 |
catalytic activity | 12 |
i mg | 12 |
specific pcr | 12 |
erk phosphorylation | 12 |
secretory phases | 12 |
live attenuated | 12 |
one day | 12 |
study provides | 12 |
acute gastroenteritis | 12 |
flow velocity | 12 |
epcam cd | 12 |
mis levels | 12 |
input parameters | 12 |
following injury | 12 |
infected colonies | 12 |
matrix proteins | 12 |
optimal policy | 12 |
reverse transcriptase | 12 |
i peak | 12 |
control signal | 12 |
singleton pregnancies | 12 |
surveillance systems | 12 |
constant flow | 12 |
lower bound | 12 |
showed similar | 12 |
given time | 12 |
complement activation | 12 |
fragment dd | 12 |
descriptive statistics | 12 |
pulmonary capillary | 12 |
healthy pregnant | 12 |
effectiveness analysis | 12 |
experimental group | 12 |
days prior | 12 |
examined whether | 12 |
middle cerebral | 12 |
asian countries | 12 |
sum test | 12 |
optimal isolation | 12 |
free equilibrium | 12 |
social networks | 12 |
environmental enrichment | 12 |
baseline values | 12 |
many different | 12 |
persistently infected | 12 |
time horizon | 12 |
recombinant proteins | 12 |
patient room | 12 |
lipid profile | 12 |
national health | 12 |
follicular phase | 12 |
irisin levels | 12 |
million cases | 12 |
stroke volume | 12 |
spontaneous preterm | 12 |
prospective cohort | 12 |
coupled receptors | 12 |
obtained using | 12 |
conditioned medium | 12 |
spleen cells | 12 |
higher scores | 12 |
construction sites | 12 |
brain tumor | 12 |
normal endometrium | 12 |
fatal outcome | 12 |
delay diagnosis | 12 |
healthcare settings | 12 |
recently reported | 12 |
model optimal | 12 |
allele frequency | 12 |
utero meconium | 12 |
genotype frequencies | 12 |
umbilical venous | 12 |
control applied | 12 |
reverse transcription | 12 |
risk group | 12 |
nasal cavity | 12 |
left ventricle | 12 |
rotavirus infection | 12 |
respiratory mechanics | 12 |
dose response | 12 |
vitro experiments | 12 |
lps administration | 12 |
body ratio | 12 |
tnf mab | 12 |
varying degrees | 12 |
differed significantly | 12 |
gas analysis | 12 |
scientific research | 12 |
tnf release | 12 |
adjoint system | 12 |
index case | 12 |
will provide | 12 |
venous catheter | 12 |
studies will | 12 |
immune globulin | 12 |
mathematical theory | 12 |
ambulatory care | 12 |
relatively small | 12 |
biologically active | 12 |
much higher | 12 |
quantified using | 12 |
eimeria stiedae | 12 |
ms patients | 12 |
patient transmission | 12 |
leishmania infantum | 12 |
uterine blood | 12 |
signalling pathways | 12 |
cell invasion | 12 |
term effects | 12 |
mechanisms involved | 12 |
hematopoietic stem | 12 |
group included | 12 |
antibody production | 12 |
information regarding | 12 |
ovarian reserve | 12 |
national university | 12 |
late pregnancy | 12 |
urine samples | 12 |
significant increases | 12 |
unintended pregnancies | 12 |
acid levels | 12 |
cell populations | 12 |
may need | 12 |
lymphoid tissues | 12 |
immune cell | 12 |
abdominal aorta | 12 |
medical records | 12 |
group iv | 12 |
specific binding | 12 |
local health | 12 |
arterial oxygen | 12 |
agile transformations | 12 |
rats exposed | 12 |
antioxidant system | 12 |
female offspring | 12 |
false positive | 12 |
undergoing ivf | 12 |
activity may | 12 |
pest populations | 12 |
glasgow coma | 12 |
may produce | 12 |
fold change | 12 |
body fat | 12 |
lipid rafts | 12 |
borne disease | 12 |
last decade | 12 |
infections among | 12 |
among groups | 12 |
clinically apparent | 12 |
various types | 12 |
matter lesions | 12 |
results provide | 12 |
situation report | 12 |
postmenopausal women | 12 |
neutralizing antibodies | 12 |
environmental conditions | 12 |
negative affect | 12 |
five days | 12 |
may alter | 12 |
liver tissues | 12 |
intracellular signaling | 12 |
fetal circulation | 12 |
factors may | 12 |
united nations | 12 |
negative results | 12 |
flail chest | 12 |
oxygen uptake | 12 |
state space | 12 |
apoptotic effects | 12 |
various organs | 12 |
intestinal mucosa | 12 |
data collected | 12 |
mice also | 12 |
per se | 12 |
muscle biopsy | 12 |
lyme disease | 12 |
highly conserved | 12 |
study indicates | 12 |
alkaline phosphatase | 12 |
also demonstrated | 12 |
decreased expression | 12 |
key factor | 12 |
clostridium perfringens | 12 |
missing data | 12 |
expression patterns | 12 |
producing cells | 12 |
medroxyprogesterone acetate | 12 |
surface expression | 12 |
image analysis | 12 |
informal control | 12 |
total cost | 12 |
clinical study | 12 |
findings provide | 12 |
civil society | 12 |
additional studies | 12 |
affected mice | 12 |
pregnant ewes | 12 |
results suggested | 12 |
trimester trophoblast | 12 |
antioxidant enzyme | 12 |
first three | 12 |
face shield | 12 |
biopsy specimens | 12 |
systemic disease | 12 |
photosystem ii | 12 |
linear model | 12 |
open heart | 12 |
nnis system | 12 |
magnetic resonance | 12 |
hospital settings | 12 |
well documented | 12 |
individuals infected | 12 |
inspiratory pressure | 12 |
fetal blood | 12 |
nosocomial respiratory | 12 |
tg kg | 11 |
basal levels | 11 |
tbars levels | 11 |
streptococcus pneumoniae | 11 |
female rats | 11 |
cfu ml | 11 |
aged years | 11 |
embryonic stem | 11 |
inbred mouse | 11 |
factor receptor | 11 |
metabolic activity | 11 |
uncomplicated pregnancies | 11 |
multiple logistic | 11 |
cellular proliferation | 11 |
acquired infection | 11 |
intravenous administration | 11 |
regulating glioblastoma | 11 |
acute ischemic | 11 |
normal saline | 11 |
different groups | 11 |
multocida infection | 11 |
approximately two | 11 |
growth restricted | 11 |
fat content | 11 |
sx amx | 11 |
recently discovered | 11 |
will allow | 11 |
host population | 11 |
lymphoid organs | 11 |
severe cases | 11 |
exclusion criteria | 11 |
optimality condition | 11 |
hubei province | 11 |
control guidelines | 11 |
intercellular adhesion | 11 |
cell responses | 11 |
every days | 11 |
maternally acquired | 11 |
financial support | 11 |
sod activity | 11 |
also associated | 11 |
vitro model | 11 |